Thymosin Alpha 1(10xVials)
CA$320.00
Thymosin Alpha 1 (Tα1) is a peptide known for its potent immunomodulatory properties. Here are the primary uses and benefits:
Uses and Benefits
-
Immune System Enhancement:
- T Cell Activation: Tα1 enhances the maturation and activity of T cells, which are crucial for adaptive immunity. It also activates natural killer cells and other immune system components, improving the body's ability to fight infections (Muscle and Brawn) (Wikipedia).
- Treatment of Viral Infections: It has been used to treat chronic viral infections like Hepatitis B and C, improving the immune response and aiding in viral clearance (Wikipedia).
-
Anti-Inflammatory Effects:
- Inflammation Reduction: Tα1 helps reduce chronic and acute inflammation by downregulating pro-inflammatory cytokines such as IL-1β and TNF-α. This makes it beneficial for conditions involving excessive inflammation (Muscle and Brawn).
-
Cancer Therapy Support:
- Cancer Treatment: Tα1 has shown promise in enhancing the immune response in cancer patients, helping to slow down tumor growth and improve the effectiveness of other cancer therapies (WJGNet).
-
Adjuvant in Vaccination:
- Vaccine Response Enhancement: Tα1 can improve the immunogenicity of vaccines, making them more effective. It has been particularly noted to enhance the response to influenza vaccines (WJGNet).
-
Chronic Disease Management:
- Autoimmune Diseases: Tα1 has been investigated for its potential to modulate the immune response in autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis, helping to reduce symptoms and manage the disease (Muscle and Brawn) (Wikipedia).
Administration and Dosage
- Forms: Thymosin Alpha 1 is typically administered via subcutaneous injection. Nasal sprays are also available for those who prefer not to use injections (Muscle and Brawn).
- Dosage: The dosage varies depending on the condition being treated. For chronic hepatitis B, the recommended dosage is 1.6 mg twice weekly for 6-12 months. For cancer therapy, dosages can range from 1.6 mg administered on varying schedules over several months (WJGNet).